Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

  • Giuseppe Luigi Banna | giuseppe.banna@nhs.net Deparment of Medical Oncology, Portsmouth Hospitals NHS Trust, United Kingdom.
  • Ornella Cantale Deparment of Medical Oncology, Portsmouth Hospitals NHS Trust, United Kingdom.
  • Melissa Bersanelli Medical Oncology Unit, Medicine and Surgery Department, University of Parma, Parma, Italy.
  • Marzia Del Re Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Alex Friedlaender Department, Geneva University Hospital, Geneva, Switzerland.
  • Alessio Cortellini Medical Oncology Unit, St. Salvatore Hospital, University of L’Aquila, Department of Biotechnological and Applied Clinical Sciences, L’Aquila, Italy.
  • Alfredo Addeo Department, Geneva University Hospital, Geneva, Switzerland.

Abstract

Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and a better outcome when combined with chemotherapy for the first-line treatment of patients with squamous and PD-L1 low advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents were responsible for less severe adverse events (AEs), particularly, immunerelated AEs. These differences could be explained by their different specific properties. Considering possible differences between anti-PD1 and anti-PD-L1 agents could be clinically relevant for treatment tailoring and inspiring new investigational approaches.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-07-21
Info
Issue
Section
Reviews
Keywords:
Immune-checkpoint inhibitor, PD1, PD-L1, lung cancer, immune-related adverse events.
Statistics
  • Abstract views: 32

  • PDF: 31
  • HTML: 0
How to Cite
Banna, G. L., Cantale, O., Bersanelli, M., Del Re, M., Friedlaender, A., Cortellini, A., & Addeo, A. (2020). Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncology Reviews, 14(2). https://doi.org/10.4081/oncol.2020.490